CSIMarket
 
Telix Pharmaceuticals Ltd  (NASDAQ: TLX)
 

Telix Pharmaceuticals Ltd's Customers Performance

TLX



 
TLX's Source of Revenues During the corresponding time, Telix Pharmaceuticals Ltd recorded a revenue increase by 2.65 % year on year, While revenue at the Telix Pharmaceuticals Ltd's corporate clients

List of TLX Customers




for the same period Telix Pharmaceuticals Ltd recorded revenue increase by 2.65 % year on year,

List of TLX Customers

Telix Pharmaceuticals Ltd's Business Units
segments    100.04 % of total Revenue
Precision Medicine    77.41 % of total Revenue
Therapeutics    1.15 % of total Revenue
Manufacturing Solutions    21.48 % of total Revenue
Inter-eliminations    8.52 % of total Revenue
China    1.22 % of total Revenue
United States    97.69 % of total Revenue
Other countries    1.13 % of total Revenue
At a point in time Precision Medicine    77.37 % of total Revenue
At a point in time Manufacturing Solutions    20.42 % of total Revenue
At a point in time Therapeutics    0.01 % of total Revenue
Over time Manufacturing Solutions    1.06 % of total Revenue
Over time Therapeutics    1.14 % of total Revenue






Telix Pharmaceuticals Ltd's Comment on Sales, Marketing and Customers



The company operates in the development, marketing, and commercialization of commercial products and product candidates, including imaging and therapeutic products in Greater China through a partnership with Grand Pharmaceutical Group Limited. It holds an exclusive worldwide license agreement with Eli Lilly and Company Ltd to develop and commercialize radiolabeled forms of olaratumab for cancer diagnosis and treatment. The company collaborates with large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies to access local expertise and funding for development and commercialization, particularly outside the United States.





Telix Pharmaceuticals Ltd’s Comment on Sales, Marketing and Customers


The company operates in the development, marketing, and commercialization of commercial products and product candidates, including imaging and therapeutic products in Greater China through a partnership with Grand Pharmaceutical Group Limited. It holds an exclusive worldwide license agreement with Eli Lilly and Company Ltd to develop and commercialize radiolabeled forms of olaratumab for cancer diagnosis and treatment. The company collaborates with large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies to access local expertise and funding for development and commercialization, particularly outside the United States.








TLX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Telix Pharmaceuticals Ltd 3,666.00 782.68 49.92 1,120
SUBTOTAL 0.00 0.00 0.00 -

Sources: Telix Pharmaceuticals Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Telix Pharmaceuticals Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Telix Pharmaceuticals Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.